Compare Citius Pharmaceuticals Inc (CTXR) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hershey Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Hershey Co trades at $162.74 (market cap $32.66B). The key difference: Hershey Co is far larger — about 2397.9× Citius Pharmaceuticals Inc's market cap, and Hershey Co pays a 3.57% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Hershey Co for 135 Days on average.
| CTXR | HSY | |
|---|---|---|
Market Cap | $13.62M | $32.66B |
Volume | 132,438 | 1,578,237 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $236.28 |
52-Week Low | $0.48 | $157.61 |
Typical Hold Time | 17 Days | 135 Days |
Enterprise Value | $3.79M | $37.79B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite beating earnings expectations for three consecutive quarters. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined significantly. Recent news highlights dividend resumption and international leadership changes while analysts maintain a cautious stance with 65.72% hold ratings.
HSY presents a mixed outlook with solid fundamentals offset by near-term challenges. The 26% upside to consensus price target of $204.62 offers potential, but cocoa cost pressures and technical bearishness warrant caution. Dividend investors may find value given the recent payout resumption, though margin compression remains a key monitorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
